MedPath

Sublingual Photobiomodulation in Parkinson's Disease

Not Applicable
Conditions
Parkinson Disease
Interventions
Device: placebo photobiomodulation
Device: photobiomodulation
Registration Number
NCT04028817
Lead Sponsor
University of Nove de Julho
Brief Summary

This study evaluates the use of photobiomodulation in the treatment of patients with Parkinson's disease. Half of participants will receive treatment with low level laser therapy and exercises in combination, while the other half will receive a placebo laser combined with exercises.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • patients with Parkinson's disease diagnosed with the criteria of the UK Parkinsons' Disease Society Brain Bank Clinical Diagnostic Criteria
  • In the stages I to III of the disease according to Hoehn & Yahr's Parkinson's disease staging scale - modified;
  • Individuals of both sexes,
  • with more than 50 years
  • who sign the informed consent form
Exclusion Criteria
  • patients who present some adverse event during the development of the study,
  • Who have another associated neurodegenerative disease,
  • Have blood dyscrasia, HIV, heart failure, hepatic or renal insufficiency, infections, neoplasias, respiratory disorders, hypophysis and hypothalamus problems.
  • Who fail to understand or perform procedures correctly because of physical and mental limitations.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group controlplacebo photobiomodulationThis group will receive placebo laser treatment combined with low intensity exercises
group treatmentphotobiomodulationThis group will receive laser treatment combined with low intensity exercises
Primary Outcome Measures
NameTimeMethod
10-meter walk test1 day

This evaluation will be carried out from the application of the tem meter walk test. The test will be performed in a straight hall, with a line 14 meters long. The first 2 meters marked, will be provided so that the patient reaches the usual walking speed, and the last 2 meters will be provided for the patient to decelerate and stop. At the start of the test, patients will receive walking guidance at a comfortable pace.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Daysi da Cruz Tobelem

🇧🇷

São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath